Odyssey Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Odyssey Therapeutics, Inc. - overview
Established
2021
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2021 by Eicke Latz, Kim Lewis, Felix Meissner, and Florian Schmidt, Odyssey Therapeutics Inc. develops anti-inflammation immunotherapies to treat inflammatory diseases and cancer. As of February 2024, Gary D. Glick is the CEO of the company.
In September 2025, Odyssey Therapeutics raised USD 213 million in series D funding from new investors Affinity Asset Advisors, Dimension Capital Management, Jeito Capital, Lightspeed Venture Partners, TPG, and Wedbush Securities. Other unspecified investors also participated in the round. Odyssey Therapeutics Inc. develops novel therapeutics for patients with autoimmune diseases using modern machine-learning techniques.
Its offerings include immunomodulators, oncology medicines, and many others.
Current Investors
OrbiMed Advisors, Colt Ventures, HBM Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.odysseytx.com
Verticals
Artificial Intelligence
Company Stage
Series D
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.